Abstract:Purpose The inhibition of immune checkpoints such as programmed cell death ligand-1 (PD-L1/CD274) with antibodies is providing novel opportunities to expose cancer cells to the immune system. Antibody based checkpoint blockade can, however, result in serious autoimmune complications because normal tissues also express immune checkpoints. As sequence-specific gene-silencing agents, the availability of siRNA has significantly expanded the specificity and range of “druggable” targets making them promising agents for precision medicine in cancer. Here, we have demonstrated the ability of a novel biodegradable dextran based theranostic nanoparticle (NP) to deliver siRNA downregulating PD-L1 in tumors. Optical imaging highlighted the importance of NP delivery and accumulation in tumors to achieve effective downregulation with siRNA NPs, and demonstrated low delivery and accumulation in several PD-L1 expressing normal tissues. Methods The dextran scaffold was functionalized with small molecules containing amine groups through acetal bonds. The NP was decorated with a Cy5.5 NIR probe allowing visualization of NP delivery, accumulation, and biodistribution. MDA-MB-231 triple negative human breast cancer cells were inoculated orthotopically or subcutaneously to achieve differences in vascular delivery in the tumors. Molecular characterization of PD-L1 mRNA and protein expression in cancer cells and tumors was performed with qRT-PCR and immunoblot analysis. Results The PD-L1 siRNA dextran NPs effectively downregulated PD-L1 in MDA-MB-231 cells. We identified a significant correlation between NP delivery and accumulation, and the extent of PD-L1 downregulation, with in vivo imaging. The size of the NP of ~ 20 nm allowed delivery through leaky tumor vasculature but not through the vasculature of high PD-L1 expressing normal tissue such as the spleen and lungs. Conclusions Here we have demonstrated, for the first time, the feasibility of downregulating PD-L1 in tumors using siRNA delivered with a biodegradable dextran polymer that was decorated with an imaging reporter. Our data demonstrate the importance of tumor NP delivery and accumulation in achieving effective downregulation, highlighting the importance of imaging in siRNA NP delivery. Effective delivery of these siRNA carrying NPs in the tumor but not in normal tissues may mitigate some of the side-effects of immune checkpoint inhibitors by sparing PD-L1 inhibition in these tissues.

Enhancing photodynamic and radionuclide therapy by small interfering RNA (siRNA)-RAD51 transfection via self-emulsifying delivery systems (SNEDDS)

Polymer‐DNA Carriers Co‐Deliver Photosensitizer and siRNA for Light‐Promoted Gene Transfection and Hypoxia‐Relieved Photodynamic Therapy

Targeting DNA damage repair mechanism by using RAD50-silencing siRNA nanoparticles to enhance radiotherapy in triple negative breast cancer

Electrostatic Attractive Self‐Delivery of siRNA and Light‐Induced Self‐Escape for Synergistic Gene Therapy

Polycation-detachable Nanoparticles Self-Assembled from Mpeg-Pcl-g-ss-pdmaema for in Vitro and in Vivo Sirna Delivery.

Unprotonatable and ROS-Sensitive Nanocarrier for NIR Spatially Activated siRNA Therapy with Synergistic Drug Effect

Investigation of a Dual Sirna/chemotherapy Delivery System for Breast Cancer Therapy

Enhanced endosomal escape of siRNA-incorporating hybrid nanoparticles from calcium phosphate and PEG-block charge-conversional polymer for efficient gene knockdown with negligible cytotoxicity

Carrier-free Delivery of Nucleic Acid and Photosensitizer Nanoparticles for Enhanced Photodynamic and Gene Antitumour Therapy

Redox-Responsive Nanoparticle-Mediated Systemic RNAi for Effective Cancer Therapy.

Solid nano-in-nanoparticles for potential delivery of siRNA

Ultrasound-sensitive siRNA-loaded nanobubbles fabrication and antagonism in drug resistance for NSCLC

Stimuli-responsive Hybrid Nanocarriers Developed by Controllable Integration of Hyperbranched PEI with Mesoporous Silica Nanoparticles for Sustained Intracellular Sirna Delivery.

Targeted Delivery of Sirna-Generating DNA Nanocassettes Using Multifunctional Nanoparticles.

Targeted Gene Silencing Using Rgd-Labeled Chitosan Nanoparticles

Dual Effect by Chemical Electron Transfer Enhanced siRNA Lipid Nanoparticles: Reactive Oxygen Species-Triggered Tumor Cell Killing Aggravated by Nrf2 Gene Silencing

Co-delivery of PD-L1- and EGFR-targeting siRNAs by synthetic PEG 12 -KL4 peptide to the lungs as potential strategy against non-small cell lung cancer

Enhanced Delivery of PEAL Nanoparticles with Ultrasound Targeted Microbubble Destruction Mediated Sirna Transfection in Human MCF-7/S and MCF-7/ADR Cells in Vitro

PD-L1 siRNA Theranostics With a Dextran Nanoparticle Highlights the Importance of Nanoparticle Delivery for Effective Tumor PD-L1 Downregulation

DNA Origami Frameworks Enabled Self-Protective Sirna Delivery for Dual Enhancement of Chemo-Photothermal Combination Therapy

Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery